Ansab Akhtar

Dr. Ansab Akhtar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Neurochemistry International
Verified
Journal Article
Closed access
Ansab AkhtarAnsab Akhtar
Ansab Akhtar
SSSangeeta Pilkhwal Sah
Sangeeta Pilkhwal Sah


13 December 2022 in ACS Omega
Verified
Journal Article
Open access
Ansab AkhtarAnsab Akhtar
Ansab Akhtar
SGShraddha Manish Gupta
Shraddha Manish Gupta
SDShubham Dwivedi
Shubham Dwivedi
DKDevendra Kumar
Devendra Kumar
MSMohamad F Shaikh
Mohamad F Shaikh
Arvind NegiArvind Negi
Arvind Negi
A robust preclinical disease model is a primary requirement to understand the underlying mechanisms, signaling pathways, and drug screening for human diseases. Although various preclinical models are available for several diseases, clinical models for Alzheimer's disease (AD) remain underdeveloped and inaccurate. The pathophysiology of AD mainly includes the presence of amyloid plaques and neurofibrillary tangles (NFT). Furthermore, neuroinflammation and free radical generation also contribute to AD. Currently, there is a wide gap in scientific approaches to preventing AD progression. Most of the available drugs are limited to symptomatic relief and improve deteriorating cognitive functions. To mimic the pathogenesis of human AD, animal models like 3XTg-AD and 5XFAD are the primarily used mice models in AD therapeutics. Animal models for AD include intracerebroventricular-streptozotocin (ICV-STZ), amyloid beta-induced, colchicine-induced, etc., focusing on parameters such as cognitive decline and dementia. Unfortunately, the translational rate of the potential drug candidates in clinical trials is poor due to limitations in imitating human AD pathology in animal models. Therefore, the available preclinical models possess a gap in AD modeling. This paper presents an outline that critically assesses the applicability and limitations of the current approaches in disease modeling for AD. Also, we attempted to provide key suggestions for the best-fit model to evaluate potential therapies, which might improve therapy translation from preclinical studies to patients with AD.



6 October 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MBMeghna Bains
Meghna Bains
JKJaspreet Kaur
Jaspreet Kaur
Ansab AkhtarAnsab Akhtar
Ansab Akhtar
AKAnurag Kuhad
Anurag Kuhad
SSSangeeta Pilkhwal Sah
Sangeeta Pilkhwal Sah